Dabrafenib 75mg Capsules$680.00
1–9 boxes
$680.00 each
10–24 boxes
8% off
25+ boxes
10% off
Dabrafenib 75mg Capsules
SKU GME1123Oncology Care
Product Introduction
Dabrafenib 75mg is a targeted treatment for cancers with susceptible BRAF V600 mutations, including melanoma. It is also combined with trametinib for certain BRAF-mutated lung, thyroid and other solid tumours.
How to use
Take the capsule dose twice daily, approximately 12 hours apart, on an empty stomach at least one hour before or two hours after food. Swallow capsules whole without opening them. A missed dose is skipped if the next dose is due within six hours.
How it works
Dabrafenib inhibits the abnormal BRAF protein driving MAPK growth signalling in susceptible cancer cells. Combining it with a MEK inhibitor blocks the pathway at a second point.
Side effects
Fever, headache, fatigue, joint pain, rash and skin thickening can occur. Combination treatment can cause significant fever with chills, dehydration or low blood pressure. Serious eye inflammation, heart problems, bleeding and new skin cancers are other important risks.
Important information
A qualifying BRAF mutation is confirmed before treatment. Skin examinations continue during therapy to identify new lesions. Fever episodes need the combination regimen's interruption and hydration plan. Blood glucose monitoring is relevant in diabetes because hyperglycaemia can occur.
Uses
- Eligible BRAF V600-mutated melanoma
- selected BRAF-mutated lung, thyroid or other solid tumours within an appropriate trametinib-containing regimen.
Benefits
Suppressing abnormal BRAF signalling can shrink responsive tumours and delay progression. Adding MEK inhibition can improve pathway control in suitable cancers and reduce some BRAF-inhibitor-associated skin complications.
Can dabrafenib be used without a BRAF mutation result?
It is selected for cancers with particular BRAF mutations. Treating a BRAF-wild-type tumour is not assumed to provide the same benefit and may have unwanted biological effects.
Is fever always an infection during combination treatment?
No. Drug-related fever is well recognised with dabrafenib/trametinib, but infection must still be considered. Fever with chills, dizziness or poor fluid intake needs prompt assessment.
Why are new skin growths examined during treatment?
BRAF inhibition can stimulate certain skin tumours through different signalling effects. New warts, changing moles or persistent sores should be examined rather than treated as ordinary rash.
Are dabrafenib and trametinib taken at the same frequency?
No. Dabrafenib is usually taken twice daily, while trametinib is once daily. Their schedules should not be made identical simply because they are prescribed together.
BRAF: growth-signalling protein that can be altered in cancer. V600 mutation: change at a specific BRAF protein position. MAPK pathway: chain of cell-growth signals. Pyrexia: fever. Hyperglycaemia: raised blood glucose.; AR: Dabrafenib 75mg كبسولات; FR: Dabrafenib 75mg gélules; PT: Dabrafenib 75mg cápsulas; ES: Dabrafenib 75mg cápsulas; RU: Dabrafenib 75mg капсулы; ID: Dabrafenib 75mg kapsul; VI: Dabrafenib 75mg viên nang; MS: Dabrafenib 75mg kapsul; TL: Dabrafenib 75mg kapsula; ZH-SG: Dabrafenib 75mg 胶囊